[Experience in treating psoriasis patients with the preparation Ditrastic].

Abstract

The results of clinical trials of ditrastic, an agent manufactured by Orion, Finland, are analyzed. The drug contains 1.5 or 3% of ditranol. Of the 59 patients treated with this drug complete resolution of clinical eruptions was achieved in 43, the condition of 10 patients considerably improved, a partial effect was observed in 4, and no effect in 2 patients. Therefore ditrastic has proved to be a highly effective agent for the treatment of psoriasis, convenient for outpatient therapy.

• Authors: A L Mashkilleĭson, I Iu Golousenko
• Journal: Vestnik dermatologii i venerologii (Vestn Dermatol Venerol) Issue 12 Pg. 51-2 ( 1989) ISSN: 0042-4609 [Print] Russia (Federation)
• Vernacular Title: Opyt lecheniia bol'nykh psoriazom preparatom "Ditrastik".
• PMID: 2633555 (Publication Type: English Abstract, Journal Article)

Chemical References

• Dermatologic Agents
• Drug Combinations
• ditrastic
• Sulfur
• Paraffin
• Anthralin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Anthralin (therapeutic use)
• Dermatologic Agents (therapeutic use)
• Drug Combinations (therapeutic use)
• Drug Evaluation
• Female
• Humans
• Male
• Middle Aged
• Paraffin (therapeutic use)
• Psoriasis (drug therapy)
• Sulfur (therapeutic use)
• Time Factors